CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 17 enrolled
Drug / intervention
Indium-111 Pentreotide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02546388
NCT02546388N/ACompleted
CompareCT.gov

Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis

Marcelo F. Di Carli, MD, FACC·interventional·Posted Sep 10, 2015·Updated Apr 9, 2020

In Brief

A clinical study evaluating Indium-111 Pentreotide and Gallium-68 DOTATATE for Sarcoidosis. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The purpose of this research study to find out if a drug called OctreoScan or DOTATATE can help doctors diagnose people with cardiac sarcoidosis better. OctreoScan and DOTATATE are both approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoidosis
CountriesUnited States
CollaboratorsMallinckrodt

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 10, 2015
Enrollment StartOct 1, 2015
Primary CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 10.8 years ago

Interventions

Indium-111 Pentreotidedrug

Gallium-68 DOTATATEdrug